New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon
Jacques Da Ndawinz, Xavier Anglaret, Eric Delaporte, Sinata Koulla-Shiro, Delphine Gabillard, Albert Minga, Dominique Costagliola, Virginie Supervie

To cite this version:
New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon

Jacques DA Ndwanz, Xavier Anglaret, Eric Delaporte, Sinata Koulla-Shiro, Delphine Gabillard, Albert Minga, Dominique Costagliola & Virginie Supervie

**Objective** To propose two new indicators for monitoring access to antiretroviral treatment (ART) for human immunodeficiency virus (HIV); (i) the time from HIV seroconversion to ART initiation, and (ii) the time from ART eligibility to initiation, referred to as delay in ART initiation. To estimate values of these indicators in Cameroon.

**Methods** We used linear regression to model the natural decline in CD4+ T-lymphocyte (CD4+ cell) numbers in HIV-infected individuals over time. The model was fitted using data from a cohort of 351 people in Côte d’Ivoire. We used the model to estimate the time from seroconversion to ART initiation and the delay in ART initiation in a representative sample of 4154 HIV-infected people who started ART in Cameroon between 2007 and 2010.

**Findings** In Cameroon, the median CD4+ cell counts at ART initiation increased from 140 cells/μL (interquartile range, IQR 73 to 210) in 2007–2009 to 163 cells/μl (IQR: 73 to 260) in 2010. The estimated average time from seroconversion to ART initiation decreased from 10.4 years (95% confidence interval, CI: 10.3 to 10.5) to 9.8 years (95% CI: 9.6 to 10.0). Delay in ART initiation increased from 3.4 years (95% CI: 3.1 to 3.7) to 5.8 years (95% CI: 5.6 to 6.2).

**Conclusion** The estimated time to initiate ART and the delay in ART initiation indicate that progress in Cameroon is insufficient. These indicators should help monitor whether public health interventions to accelerate ART initiation are successful.

**Abstract** in English, Arabic, Chinese, French, Russian and Spanish at the end of each article.
living with HIV and who started ART in the month of October in the years 2007–2010 were reviewed to obtain sociodemographic and CD4+ cell count data, including gender, age at ART initiation, date of ART initiation and CD4+ cell count before ART initiation. Most participants were women (2829, 68.1%), and median age at ART initiation was 35 years (Table 1).

The second data set can be obtained from an observational cohort including individuals with a known or reliably estimated date of HIV seroconversion and repeated measurements of the CD4 cell count over time. As there was no such cohort study in Cameroon, we used data from a cohort of blood donors who had documented seroconversion between donations in Côte d’Ivoire (ANRS 1220 Primo-CI study).11,12 Blood donors had been invited to participate if they met the following criteria: diagnosed with HIV during a blood donation; HIV-seronegative at the preceding donation; less than 36 months had elapsed since seroconversion. The date of seroconversion was estimated as the midpoint between the last negative and the first positive HIV test. We used data on 351 cohort participants in our analyses, with 3037 CD4+ cell count measurements before ART initiation or death; CD4+ cell counts obtained more than 10 years after seroconversion were discarded to avoid a selection bias for slow progressors. Median age at seroconversion was 28.8 years and 60.7% (213) were men (Table 2).

The median time between the last negative and first positive HIV test was 8.5 months and the median time from seroconversion to inclusion into the cohort was 9.0 months. The median CD4+ cell count at cohort inclusion was 450 cells/μL and the median number of CD4+ cell measurements per individual was eight.

Blood samples from the participants were collected at inclusion into the cohort and every six months thereafter to measure the CD4+ cell count.

**Analyses**

The analysis was completed in three steps. First, we modelled the natural decline in CD4+ cell counts in HIV-infected individuals who had not yet received ART, using data from the seroconversion cohort. Second, we used the model to estimate the average time from seroconversion to ART eligibility from the estimated date of HIV seroconversion. The date of seroconversion was estimated as the midpoint between the last negative and first positive HIV test and had a measure of CD4+ cell count at treatment initiation, Cameroon.

Then, we calculated the delay in ART initiation in Cameroon by subtracting the average time between HIV seroconversion and ART eligibility from the average time between HIV seroconversion and ART initiation.

We first used a linear mixed model13 to describe the natural decline in CD4+ cell counts in ART-naive HIV-infected individuals with estimated dates of HIV seroconversion and repeated measurements of the CD4+ cell count over time. To take into account the correlation of repeated measurements in a given individual, the parameters were allowed to vary from one individual to another through a random intercept and slope. CD4+ cell count data were square-root transformed to normalize their distribution.14 The model equations are as follows:

\[
\sqrt{CD4_{ij}} = \beta_0 + \beta_n x_{ij} + \beta_i + \epsilon_{ij}
\]

\[
\sqrt{CD4_{i0}} = \alpha_0 + \alpha_1 x_{i1} + \ldots + \alpha_{ik} x_{ik} + b_0
\]

\[
\beta_1 = \beta_0 + \beta_1 x_{i1} + \ldots + \beta_k x_{ik} + b_1
\]

where \(CD4_{ij}\) is the CD4+ cell count measured at the \(j\)th visit of the \(i\)th individual; \(CD4_{i0}\) is the estimated CD4+ cell count at HIV seroconversion, defined as time 0 in the model; \(\beta_1\) is the CD4+ cell count slope; \(t_i\) is the interval from the estimated date of seroconversion to the \(j\)th visit; and \(\epsilon_{ij}\) is the residual error.

**Table 1.** Characteristics of people living with HIV who started antiretroviral treatment, and had a measure of CD4+ cell count at treatment initiation, Cameroon 2007–2010

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>People who started ART</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 4154)</td>
</tr>
<tr>
<td>Number of women (%)</td>
<td>28.29 (68.1)</td>
</tr>
<tr>
<td>Median age at ART initiation, years (IQR)</td>
<td>35.0 (29.0 to 43.0)</td>
</tr>
<tr>
<td>Median CD4+ cell count at ART initiation, cells/μL (IQR)</td>
<td>2007–2009 All</td>
</tr>
<tr>
<td></td>
<td>Women</td>
</tr>
<tr>
<td></td>
<td>Men</td>
</tr>
<tr>
<td></td>
<td>2010 All</td>
</tr>
<tr>
<td></td>
<td>Women</td>
</tr>
<tr>
<td></td>
<td>Men</td>
</tr>
</tbody>
</table>

ART: antiretroviral therapy; HIV: human immunodeficiency virus; IQR: interquartile range. Notes: People included in the study were older than 15 years and started ART in the month of October each year. The ART eligibility threshold was 200 cells/μL in 2007–2009 and 350 cells/μL in 2010.

**Table 2.** Characteristics of ANRS 1220 Primo-CI cohort participants in Côte d’Ivoire

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Cohort participants</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 351)</td>
</tr>
<tr>
<td>Number of women (%)</td>
<td>138 (39.3)</td>
</tr>
<tr>
<td>Median age at seroconversion, years (IQR)</td>
<td>28.8 (24.5 to 34.4)</td>
</tr>
<tr>
<td>Median time between last negative and first positive HIV test, months (IQR)</td>
<td>8.5 (3.4 to 20.3)</td>
</tr>
<tr>
<td>Median time between estimated date of seroconversion and cohort inclusion, months (IQR)</td>
<td>9.0 (4.9 to 18.9)</td>
</tr>
<tr>
<td>Median CD4+ cell count at cohort inclusion, cell/μL (IQR)</td>
<td>450 (313 to 612)</td>
</tr>
<tr>
<td>Median number of CD4+ cell count measurements (IQR)</td>
<td>8.0 (3.0 to 13.0)</td>
</tr>
<tr>
<td>Median time between two consecutive CD4+ cell count measurements, months (IQR)</td>
<td>6.0 (5.9 to 6.1)</td>
</tr>
<tr>
<td>Median cohort follow-up, years (IQR)</td>
<td>5.6 (3.6 to 8.2)</td>
</tr>
</tbody>
</table>

HIV: human immunodeficiency virus; IQR: interquartile range. Data sources: ANRS 1220 Primo-CI.11,13
Both the CD4+ cell count at seroconversion and the CD4+ slope may be influenced by covariates. \( x_{i} \) represents the \( k \)th covariate; \( \alpha_i \) and \( \beta_i \) are respectively the fixed-effect intercept and slope for the \( k \)th covariate; \( \alpha_0 \) and \( \beta_0 \) are respectively the baseline intercept and slope; and \( \alpha_u \) and \( \beta_u \) are respectively the random intercept and slope for the \( th \) individual.

\[ \sqrt{CD_{4i}} - E(\sqrt{CD_{4i}}) \]

\[ E(\beta_i) \]

(2)

where \( CD_{4i} \) is a given CD4+ cell count, \( E(\sqrt{CD_{4i}}) \) and \( E(\beta_i) \) are expected values of \( \sqrt{CD_{4i}} \) (the square root of the CD4+ cell counts at seroconversion) and \( \beta_i \), (rate of CD4+ cell count decline) obtained by fitting Equation (1) to data from seroconverters.

Second, we used Equation (2), to calculate, for each seroconverter, the time from seroconversion to specified CD4+ count thresholds. From these individual times we calculated the average time from seroconversion to ART eligibility.

Third, we calculated the time from seroconversion to ART initiation, using Equation (2), we need to know the CD4+ cell count at ART initiation, the CD4+ cell count at HIV seroconversion and the average rate of CD4+ cell count decline. Many HIV-infected individuals starting ART have only one available CD4+ cell count before ART initiation, because they are already eligible for ART when HIV infection is diagnosed. Thus, the CD4+ cell count at seroconversion and the rate of CD4+ cell count decline are both unknown. We generated the values of these two parameters for each HIV-infected individual starting ART by using data from seroconverters.\(^{11,12}\) Specifically, for each individual included in the survey conducted in Cameroon, we simulated 200 sets of CD4+ cell count values at seroconversion and rates of CD4+ cell count decline, as follows. Square-root transformed values of the CD4+ cell count at HIV seroconversion and CD4+ cell count slopes in ANRS 1220 PrimoCl cohort participants were fitted with a joint bivariate normal distribution.\(^{15}\) This distribution was used to simulate the 200 sets of values for each surveyed individual. Using each set of values, along with CD4+ cell counts measured at ART initiation and Equation (2), we calculated, for each surveyed individual, 200 time intervals between seroconversion and ART initiation. We estimated the average time from seroconversion to ART initiation by averaging the results for each surveyed individual. Finally, we calculated the delay in ART initiation.

The eligibility for ART initiation in Cameroon was raised from 200 to 350 cells/µL in August 2010. We therefore calculated the average time from seroconversion to ART initiation and delay in ART initiation using the estimated average time from seroconversion to 200 cells/µL for individuals who initiated ART before August 2010. For individuals who initiated ART after August 2010, we used the estimated average time from seroconversion to 350 cells/µL.

To assess the robustness of our results, we performed sensitivity analyses which considered two scenarios of HIV virulence. First we assumed higher virulence leading to 5% lower CD4+ cell count at HIV seroconversion and 5% higher CD4+ cell count slope. Second we assumed lower virulence leading to 5% higher CD4+ cell count at HIV seroconversion and 5% lower CD4+ cell count slope. These assumptions were motivated by findings that showed a 25% decrease in the CD4+ cell count at seroconversion over more than 20 years,\(^{16}\) while our study only considered individuals who initiated ART between 2007 and 2010. We compared the results from the sensitivity analyses with the main estimates using the Z-test. All analyses were performed using Stata version 11.1 (StataCorp. LP, College Station, United States of America).

Results

Model fitting

By fitting the mixed model to the seroconverter data, we estimated that the mean CD4+ cell count at seroconversion was 539 cells/µL (95% confidence intervals: CI: 516 to 562) and that the mean CD4+ cell decline in the first year after seroconversion was 53 cells/µL (95% CI: 51 to 56). Higher CD4+ cell counts at cohort inclusion and longer intervals from seroconversion to cohort inclusion were associated with higher CD4+ cell counts at seroconversion (\(P < 0.001\); Table 3). In addition, higher CD4+ cell counts at cohort inclusion were associated with a more rapid CD4+ cell decline (\(P = 0.009\); Table 3). None of the other covariates was significantly associated with the intercept or slope.

Time to ART eligibility

We replaced the parameters in Equation (2) with their estimates from the previous step to calculate the time from HIV seroconversion to ART eligibility:

\[ t_i = (\sqrt{CD_{4i}} - (12.035 + 0.973t_{i0} + 0.02CD_{4i0})) / (-0.676 - 0.001CD_{4i0}) \]

(3)

where \( CD_{4i} \) is the CD4+ cell count ART eligibility threshold, \( t_{i0} \) is the estimated number of years from seroconversion to cohort inclusion, and \( CD_{4i0} \) is the CD4+ cell count at cohort inclusion.

The average times from seroconversion to CD4+ cell counts of less than 350 and 200 cells/µL were 4.0 and 7.0 years, respectively. The corresponding median times were 3.8 and 7.1 years (Table 4).

Cameroon indicators

Women had a higher CD4+ cell count at ART initiation than men (\(P < 0.001\)). The median CD4+ cell count at ART initiation increased significantly from 123 cells/µL in 2007-2009 to 147 cells/µL in 2010 among men, and from 147 cells/µL in 2007-2009 to 170 cells/µL in 2010 among women.

Time to ART initiation

The estimated average time from seroconversion to ART initiation fell from 10.4 years (95% CI: 10.3 to 10.5) in 2007–2009 to 9.8 years (95% CI: 9.6 to 10.0) in 2010 (Table 5); the corresponding median times were 9.9 and 9.2 years. The time was significantly shorter for women than men in 2007–2009 (10.2 versus 10.9 years, \(P < 0.01\)), while the difference was no
longer significant in 2010 (9.7 versus 10.0 years, \( P = 0.36 \)).

### Delay in ART initiation

The estimated delay in ART initiation is shown in Table 5. Overall, the delay increased from 3.4 years (95% CI: 3.1 to 3.7) in 2007–2009 to 5.8 years (95% CI: 5.6 to 6.2) in 2010. Women had shorter delays than men (3.2 versus 3.9 years in 2007–2009, and 5.6 versus 6.0 years in 2010).

### Sensitivity analyses

The results from our sensitivity analysis are shown in Table 6. Assuming a 5% increase in HIV virulence led to a 1.1–1.3 year shorter average time from seroconversion to ART initiation, corresponding to an 11–12% decrease (\( P < 0.0001 \)). While assuming a 5% decrease in HIV virulence led to a 1.3–1.4 year longer average time, corresponding to an 11–14% increase (\( P < 0.0001 \)). In contrast, the delay in ART initiation was not significantly changed under the two sensitivity analysis scenarios except for the overall value in 2010 (\( P = 0.002 \)) and the value among women in 2010 (\( P < 0.05 \)), where we found a 9–10% decrease when assuming a 5% increase in HIV virulence and a 12–13% increase when assuming a 5% decrease in HIV virulence.

### Discussion

Delays in starting ART are lost opportunities for both the individual and the community. Therefore expanding ART programmes and accelerating ART initiation will be important to control the HIV epidemic. Here, we propose a method to estimate two new population-level indicators. Delay in ART initiation quantifies the loss of opportunity for people living with HIV. The time from HIV seroconversion to ART initiation quantifies the number of years that HIV-infected individuals were able to transmit HIV.

Our approach requires two data sets. First, data on the natural history of the CD4+ cell count decline during HIV infection. Second, data on CD4+ cell counts at ART initiation among individuals who are representative of the population of interest. The first data set can be obtained from the cohort of seroconverters in a nearby country if not available in the country of interest. Such cohorts exist in low-, middle- and high-income countries.\(^b\) The second data set is collected in most countries, as CD4+ cell count is an important parameter for the decisions of ART initiation and clinical management.\(^b\) Even in countries implementing ART initiation regardless of CD4+ count levels. Thus, our approach can be used to estimate the delay in ART initiation in most settings.

Our approach is based on two main assumptions. First, we converted CD4+ cell counts into time since HIV seroconversion. We assumed that individuals with low CD4+ cell counts had been infected with HIV longer than individuals with high CD4+ cell counts. This is a reasonable assumption at the population level. Other studies have used a similar approach to estimate the time from seroconversion to ART eligibility at the population level.\(^b\) Second, we assumed that all HIV-infected individuals are eligible for ART only when the CD4+ threshold is reached. In reality, some individuals with symptomatic HIV disease are eligible for ART regardless of CD4+ cell count.\(^b\) Therefore, we may have underestimated the average time from seroconversion to ART eligibility and thus underestimated the delay in ART initiation. We did not account for people that have not yet initiated ART.

---

**Table 3. Influence of selected characteristics of ANRS 1220 Primo-CI cohort participants on the CD4+ cell count at seroconversion and its slope, as estimated from the linear mixed model**

<table>
<thead>
<tr>
<th>Effect</th>
<th>Coefficient (95% CI)</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fixed effect</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Square-root CD4+ cell count intercept</td>
<td>12.035 (11.358 to 12.712)</td>
<td>&lt; 0.001&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>CD4+ cell count at cohort inclusion (per 1 cell/μL increase)</td>
<td>0.020 (0.019 to 0.021)</td>
<td>&lt; 0.001&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Time from HIV seroconversion to cohort inclusion (per one-year increase)</td>
<td>0.973 (0.672 to 1.273)</td>
<td>&lt; 0.001&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Square-root CD4+ cell count slope (cells/μL decrease per year)</td>
<td>−0.676 (−0.972 to −0.379)</td>
<td>&lt; 0.001&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>CD4+ cell count at cohort inclusion (per 1 cell/μL increase)</td>
<td>−0.001 (−0.001 to −0.000)</td>
<td>0.009&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Time from HIV seroconversion to cohort inclusion (per one-year increase)</td>
<td>−0.065 (−0.186 to 0.056)</td>
<td>0.292&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Random effect</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intercept variance</td>
<td>2.007 (1.390 to 2.898)</td>
<td>&lt; 0.001&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Slope variance</td>
<td>0.525 (0.394 to 0.701)</td>
<td></td>
</tr>
<tr>
<td>Covariance between intercept and slope</td>
<td>−0.165 (−0.430 to 0.101)</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup> Wald test. The likelihood ratio test rejected the null hypothesis that all coefficients were simultaneously equal to 0.

<sup>b</sup> The threshold is a CD4+ cell count less than 200 cells/μL.

---

**Table 4. Estimated time from HIV seroconversion to ART eligibility**

<table>
<thead>
<tr>
<th>HIV seroconverters</th>
<th>2010 WHO ART eligibility threshold&lt;sup&gt;a&lt;/sup&gt;</th>
<th>2006 WHO ART eligibility threshold&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean years (95% CI)</td>
<td>Median years (IQR)</td>
</tr>
<tr>
<td>All</td>
<td>4.0 (3.7 to 4.3)</td>
<td>3.8 (2.0 to 5.7)</td>
</tr>
<tr>
<td>Women</td>
<td>4.1 (3.6 to 4.5)</td>
<td>3.9 (2.2 to 5.9)</td>
</tr>
<tr>
<td>Men</td>
<td>4.0 (3.6 to 4.3)</td>
<td>3.7 (1.9 to 5.7)</td>
</tr>
</tbody>
</table>

Art: antiretroviral therapy; CI: confidence interval; HIV: human immunodeficiency virus; IQR: interquartile range; WHO: World Health Organization.

<sup>a</sup> The threshold is a CD4+ cell count less than 350 cells/μL.

<sup>b</sup> The threshold is a CD4+ cell count less than 200 cells/μL.

---

\( P = 0.05 \)

---

\( P = 0.0001 \)

---

\( P < 0.0001 \)
In Cameroon, we found that the time between HIV seroconversion and ART initiation fell between 2007–2009 and 2010. However, the delay in ART initiation increased during the same period because the ART eligibility threshold was lowered. We also found that women who started ART in 2007–2009 had shorter delays than men, whereas no significant sex difference was found in 2010. This reflects a small sex difference in the CD4+ cell counts at ART initiation in 2010.

**Limitations**

As there was no available cohort of seroconverters in Cameroon, we used data from a cohort in Côte d’Ivoire. HIV type 1 (HIV-1) genetic diversity is high in Cameroon, while in Côte d’Ivoire, the HIV-1 CRF 02_AG variant predominates. However, a study conducted in Cameroon and Senegal showed no difference in clinical progression between patients infected with CRF 02_AG and patients infected with other variants. In addition, our estimates of the CD4+ cell count at seroconversion and the CD4+ cell count decline are similar to those obtained in other sub-Saharan countries, suggesting that any differences in disease progression at the population level would be small. Finally, it is conceivable that HIV has become more or less virulent over the course of the pandemic.

Our sensitivity analyses showed that changes in HIV virulence affected the average time between HIV seroconversion and ART initiation, while the delay in ART initiation was less sensitive to assumptions about such changes.

The results from Cameroon show that some progress has been made in reducing late ART initiation. Changes in ART guidelines and decentralization of HIV care could have affected this decrease. In particular, as new guidelines were introduced, patients in care with CD4+ cell counts above 200 cells/µL could have become eligible for ART earlier. Likewise, decentralization of HIV care could have made ART available earlier at the rural level. However, the estimated time of approximately 10 years to initiate ART and approximately 6 years for the delay in ART initiation indicate that the progress is insufficient and calls for interventions that accelerate ART initiation in Cameroon.

In conclusion, to optimize the control of HIV infection both at individual and community level, ART initiation will need to accelerate to close the gap between the WHO-recommended and actual timing of ART initiation. The proposed indicators should help monitor...

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.

Research

delay in starting antiretrovirals, Cameroon

Delay in starting antiretrovirals, Cameroon

Jacques DA Ndawinz et al.
**Résumé**

**Objectif** Proposer deux nouveaux indicateurs pour évaluer l’accès au traitement antirétroviral (TAR) contre le virus de l’immunodéficience humaine (VIH); (i) le délai entre la séroconversion et le VIH et le début du TAR, et (ii) le délai entre l’éligibilité au TAR et le début du TAR, appelé «délai écoulé avant le début du TAR». Estimer l’utilité de ces indicateurs au Cameroun.

**Méthodes** Nous avons utilisé une régression linéaire pour modeliser le déclin naturel au fil du temps du nombre de lymphocytes T CD4+ (cellule CD4+) chez les individus infectés par le VIH. Le modèle a été conçu à l’aide de données provenant d’une cohorte de 351 individus de Côte d’Ivoire. Nous l’avons utilisé pour estimer le délai entre la séroconversion et le début du TAR ainsi que le retard dans l’accès au TAR sur un échantillon représentatif de 4154 individus infectés par le VIH ayant commencé un TAR au Cameroun entre 2007 et 2010.

**Résultats** Au Cameroun, le taux médian de CD4+ au début du TAR est passé de 140 cellules/ul ( intervalle interquartile, IQR: de 66 à 210) en 2007–2009 à 163 cellules/ul (IQR: de 73 à 260) en 2010. Le délai moyen estimé entre la séroconversion et le début du TAR est passé de 10,4 années (intervalle de confiance, IC, à 95%: de 10,3 à 10,5) à 9,8 années (IC à 95%: de 9,6 à 10,0). Le retard dans l’accès au TAR est passé de 3,4 années (IC à 95%: de 3,1 à 3,7) à 5,8 années (IC à 95%: de 5,6 à 6,2).

**Conclusion** Les estimations du délai entre la séroconversion et le début du TAR et du retard dans l’accès au TAR indiquent que les progrès accomplis au Cameroun sont insuffisants. Ces indicateurs devraient aider à évaluer l’efficacité des interventions de santé publique visant à accélérer l’accès au TAR.

**Conclusión** Proporcionar dos nuevos indicadores para evaluar el acceso al tratamiento antirretroviral (ART) para el virus de la inmunodeficiencia humana (VIH); (i) el tiempo desde la seroconversión del VIH hasta el inicio del TAR, y (ii) el tiempo desde la elegibilidad al TAR hasta el inicio del mismo, referido como retraso en el inicio del TAR. Estimar el utilidad de los indicadores en Camerún.

**Métodos** Se utilizó la regresión lineal para modelizar la disminución natural de la cantidad de linfocitos T CD4+ (célula CD4+) en los individuos infectados por el VIH con el tiempo. El modelo se adaptó utilizando datos de una cohorte de 351 individuos en Côte d’Ivoire. Se utilizó el modelo para estimar el tiempo entre la seroconversión y el inicio del TAR y el retraso en el inicio del TAR en una muestra representativa de 4154 individuos infectados por el VIH que iniciaron el TAR en Camerún entre 2007 y 2010.

**Resultados** En Camerún, la media del recuento de células CD4+ en el inicio del TAR creció de 140 células/ul (rango intercuartílico, RIC: de 66 a 210) en 2007–2009 a 163 células/ul (RIC: de 73 a 260) en 2010. El tiempo medio estimado desde la seroconversión hasta el inicio del TAR descendió de 10,4 años (intervalo de confianza, IC, del 95%: de 10,3 a 10,5) a 9,8 años (IC del 95%: de 9,6 a 10,0). El retraso en el inicio del TAR aumentó de 3,4 años (IC del 95%: de 3,1 a 3,7) a 5,8 años (IC del 95%: de 5,6 a 6,2).

**Conclusión** El tiempo estimado para iniciar el TAR y el retraso en el inicio del TAR indican que el progreso en Camerún es insuficiente. Estos indicadores deberían ayudar a monitorear si las intervenciones de salud pública para acelerar el inicio del TAR son eficaces.
References


